BRIACELL THERAPEUTICS CORP.: 10-Q filed 2023-03-16
What BRIACELL THERAPEUTICS CORP. reported in its quarterly report filed 2023-03-16 (fiscal Q2 2023): 29 published measures, 87 facts as tagged in accession 0001493152-23-007796.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2023-03-16
- Fiscal period
- fiscal Q2 2023
- Accession
- 0001493152-23-007796 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BRIACELL THERAPEUTICS CORP. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-01-31 | 34,161,267 | USD | |
| At 2022-07-31 | 42,577,041 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-01-31 | -1,280,586 | USD | |
| At 2022-10-31 | 10,334,332 | USD | |
| At 2022-07-31 | 10,328,932 | USD | |
| At 2022-01-31 | 16,425,698 | USD | |
| At 2021-10-31 | 1,583,777 | USD | |
| At 2021-07-31 | -27,671,721 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-01-31 | 33,500,236 | USD | |
| At 2022-07-31 | 41,041,652 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-11-01 to 2023-01-31 | -11,881,762 | USD | 92 |
| 2022-08-01 to 2023-01-31 | -12,988,303 | USD | 184 |
| 2021-11-01 to 2022-01-31 | 11,160,507 | USD | 92 |
| 2021-08-01 to 2022-01-31 | -16,372,978 | USD | 184 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-08-01 to 2023-01-31 | -7,494,122 | USD | 184 |
| 2021-08-01 to 2022-01-31 | -4,334,808 | USD | 184 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-08-01 to 2023-01-31 | -47,294 | USD | 184 |
| 2021-08-01 to 2022-01-31 | -4,952,192 | USD | 184 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-01-31 | -73,338,140 | USD | |
| At 2022-07-31 | -60,349,837 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-11-01 to 2023-01-31 | 15,518,018 | shares | 92 |
| 2022-08-01 to 2023-01-31 | 15,518,018 | shares | 184 |
| 2021-11-01 to 2022-01-31 | 15,788,827 | shares | 92 |
| 2021-08-01 to 2022-01-31 | 15,547,497 | shares | 184 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-11-01 to 2023-01-31 | 15,518,018 | shares | 92 |
| 2022-08-01 to 2023-01-31 | 15,518,018 | shares | 184 |
| 2021-11-01 to 2022-01-31 | 18,405,614 | shares | 92 |
| 2021-08-01 to 2022-01-31 | 15,547,497 | shares | 184 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-11-01 to 2023-01-31 | -0.77 | USD/shares | 92 |
| 2022-08-01 to 2023-01-31 | -0.84 | USD/shares | 184 |
| 2021-11-01 to 2022-01-31 | 0.71 | USD/shares | 92 |
| 2021-08-01 to 2022-01-31 | -1.05 | USD/shares | 184 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-11-01 to 2023-01-31 | -0.77 | USD/shares | 92 |
| 2022-08-01 to 2023-01-31 | -0.84 | USD/shares | 184 |
| 2021-11-01 to 2022-01-31 | 0.04 | USD/shares | 92 |
| 2021-08-01 to 2022-01-31 | -1.05 | USD/shares | 184 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-11-01 to 2023-01-31 | 266,844 | USD | 92 |
| 2022-08-01 to 2023-01-31 | 1,378,785 | USD | 184 |
| 2021-11-01 to 2022-01-31 | 814,876 | USD | 92 |
| 2021-08-01 to 2022-01-31 | 1,333,010 | USD | 184 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-11-01 to 2023-01-31 | -4,486,323 | USD | 92 |
| 2022-08-01 to 2023-01-31 | -9,889,474 | USD | 184 |
| 2021-11-01 to 2022-01-31 | -3,646,809 | USD | 92 |
| 2021-08-01 to 2022-01-31 | -5,931,618 | USD | 184 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-01-31 | 33,938,561 | USD | |
| At 2022-07-31 | 42,346,700 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-08-01 to 2022-01-31 | 979 | USD | 184 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-01-31 | 670,413 | USD | |
| At 2022-07-31 | 941,087 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-01-31 | 222,704 | USD | |
| At 2022-07-31 | 230,339 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-01-31 | 8,928 | USD | |
| At 2022-07-31 | 24,103 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-11-01 to 2023-01-31 | 4,486,323 | USD | 92 |
| 2022-08-01 to 2023-01-31 | 9,889,474 | USD | 184 |
| 2021-11-01 to 2022-01-31 | 3,646,809 | USD | 92 |
| 2021-08-01 to 2022-01-31 | 5,931,618 | USD | 184 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-11-01 to 2023-01-31 | 3,053,357 | USD | 92 |
| 2022-08-01 to 2023-01-31 | 6,308,572 | USD | 184 |
| 2021-11-01 to 2022-01-31 | 1,708,179 | USD | 92 |
| 2021-08-01 to 2022-01-31 | 2,583,815 | USD | 184 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-01-31 | 15,518,018 | shares | |
| At 2022-07-31 | 15,518,018 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-01-31 | -138,684 | USD | |
| At 2022-07-31 | -138,684 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-11-01 to 2023-01-31 | -11,881,762 | USD | 92 |
| 2022-08-01 to 2023-01-31 | -12,988,303 | USD | 184 |
| 2021-11-01 to 2022-01-31 | 11,160,507 | USD | 92 |
| 2021-08-01 to 2022-01-31 | -16,372,978 | USD | 184 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-11-01 to 2023-01-31 | -11,881,762 | USD | 92 |
| 2022-08-01 to 2023-01-31 | -12,988,303 | USD | 184 |
| 2021-11-01 to 2022-01-31 | 704,359 | USD | 92 |
| 2021-08-01 to 2022-01-31 | -16,372,978 | USD | 184 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-11-01 to 2023-01-31 | 1,432,966 | USD | 92 |
| 2022-08-01 to 2023-01-31 | 3,580,902 | USD | 184 |
| 2021-11-01 to 2022-01-31 | 1,938,630 | USD | 92 |
| 2021-08-01 to 2022-01-31 | 3,347,803 | USD | 184 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-08-01 to 2023-01-31 | 7,635 | USD | 184 |
| 2021-08-01 to 2022-01-31 | 7,636 | USD | 184 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-11-01 to 2023-01-31 | -7,395,439 | USD | 92 |
| 2022-08-01 to 2023-01-31 | -3,098,829 | USD | 184 |
| 2021-11-01 to 2022-01-31 | 14,807,316 | USD | 92 |
| 2021-08-01 to 2022-01-31 | -10,441,360 | USD | 184 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-08-01 to 2023-01-31 | -15,175 | USD | 184 |
| 2021-08-01 to 2022-01-31 | 14,592 | USD | 184 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-08-01 to 2023-01-31 | 119,171 | USD | 184 |
| 2021-08-01 to 2022-01-31 | 314,143 | USD | 184 |
Inspect the source
- Entity
- BRIACELL THERAPEUTICS CORP. / CIK 0001610820
- Captured
- 2026-09-20T09:26:46.138Z
- SEC response SHA-256
9b120e952e46202c087d84b15420884d11dabee9617ee209952acee5219f65e1
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001610820.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))